Professor John J.P. Kastelein MD PhD

John J.P. Kastelein is the Professor of Medicine and Chairman of the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease and is Director of the Atherosclerosis Research Group. He is an internationally recognized expert on the diagnosis and treatment of lipid and lipoprotein disorders, in particular, familial hypercholesterolaemia, and research in the area of molecular biology of cholesterol transport.

Professor Kastelein is a member of the Royal Dutch Society for Medicine and Physics, the Council for Basic Science of the American Heart Association and the European Atherosclerosis Society. He also is a board member of the International Task Force for CHD Prevention.

He has published over 300 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA and Circulation, and was awarded an Established Investigatorship of the Dutch Heart Foundation. He also serves on a number of executive and steering committees of lipid-lowering intervention trials, including the IDEAL, TNT, CAPTIVATE, ENHANCE and torcetrapib imaging and morbidity and mortality studies.

Professor Kastelein received his medical degree from the University of Amsterdam in 1980 and subsequently trained in internal medicine at the Academic Medical Center of the University of Amsterdam. He also trained in medical genetics, lipidology and molecular biology at the University of British Columbia, Vancouver, Canada. He has set up a foundation for the active identification of patients with classical familial hypercholesterolaemia in the Netherlands, of which he holds the Medical Directorship.


Most recent publications:

Ridker PM, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Baseline characteristics of participants in the JUPITER trial, a randomized placebocontrolled primary prevention trial of statin therapy among individuals with low lowdensity lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007;100:1659-64.
www.ncbi.nlm.nih.gov/sites/entrez

Barter P, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komada M, Lopez- Sendon J, Mosca L, Tardif J-C, Waters DD, Shear CL, Rankin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, Nov 5. published on-line.
www.ncbi.nlm.nih.gov/sites/entrez


Most cited publications:

LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, Gotto AM, Greten H, Kastelein JJP, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
www.ncbi.nlm.nih.gov/sites/entrez

Bisoendial RJ, Hovingh GK, Levels JHM, Lerch PG, Andresen I, Hayden MR, Kastelein JJP, Stroes ESG. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003;107:2944-8.
www.ncbi.nlm.nih.gov/sites/entrez

de Grooth GJ, Kuivenhoven JA, Stalenhoef AFH, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJP. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105:2159-65
www.ncbi.nlm.nih.gov/sites/entrez

van Dam MJ, de Groot E, Clee SM, Hovingh GK, Roelants R, Brooks-Wilson A, Zwinderman AH, Smit AJ, Smelt AHM, Groen AK, Hayden MR, Kastelein JJP. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet 2002;359:37-42.
www.ncbi.nlm.nih.gov/sites/entrez